Indication for Conservative Treatment in chronie Rhinosinusitis
Rhikio Ashikawa
openalex +2 more sources
SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. [PDF]
David de Bono
openalex +1 more source
Data sources used in bibliometrics 1978–2022: From proprietary databases to the great wide open
Abstract Traditionally, the bibliometric community has relied heavily on secondary data sources, most prominently the Science Citation Index. By analyzing three key journals, we detected trends in the data sources used over a 45‐year period (1978–2022).
Camilla Hertil Lindelöw+2 more
wiley +1 more source
Indication of Conservative Treatment for Chronic Paranasal Sinusitis
Minoru Okuda
openalex +2 more sources
The conservative treatment of mallet finger with a simple splint: a case report. [PDF]
A K Maitra, B Dorani
openalex +1 more source
Abstract This paper tackles the problem of robust and accurate fixed‐time tracking in human–robot interaction and deals with uncertainties. This work introduces a control approach for a wearable exoskeleton designed specifically for rehabilitation tasks.
Mahmoud Abdallah+4 more
wiley +1 more source
Conservative Treatment of Neonatal Brachial Plexus Palsy: A Narrative Review. [PDF]
Boetto V+9 more
europepmc +1 more source
Sodium manganese hexacyanoferrate (NaMnHCF) is a promising cathode for sodium‐ion batteries due to its LFP‐like voltage profile and cost‐effective composition. This study examines its cycling performance with hard carbon anodes, highlighting Na+ inventory loss as a key degradation factor.
Sebastian Büchele+15 more
wiley +1 more source
Outcome of Conservative Treatment of Odontoid Fractures in Elderly Patients Over 80 Years Old. [PDF]
Speldova A+4 more
europepmc +1 more source
Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit+6 more
wiley +1 more source